Tirzepatide Meta-50 Pen

PEPTIVA TIRZEPATIDE META-50 PEN is a synthetic dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, manufactured to be structurally identical to the 39-amino acid peptide used in clinical research programmes. This compound acts on two distinct incretin receptor pathways simultaneously — binding to both GIP and GLP-1 receptors with high affinity. In preclinical and clinical research settings, Tirzepatide has demonstrated significant effects on glucose metabolism, insulin sensitivity, gastric motility, and energy balance regulation. The SURPASS and SURMOUNT clinical trial programmes, published in The New England Journal of Medicine, reported unprecedented efficacy in glycaemic control and body weight reduction studies. Tirzepatide's unique dual-agonist mechanism allows it to enhance glucose-dependent insulin secretion via both GIP and GLP-1 pathways, suppress inappropriate glucagon secretion, delay gastric emptying, and reduce food intake through central appetite regulation in the hypothalamus. It is currently one of the most extensively studied peptides in metabolic research worldwide.